The invention provides a kind of recombination oncolytic herpes simplex virus (oHSV), it comprises specificity at the non-HSV part of molecule (albumen, lipid or Carbohydrate Antigens determinant) present on cell (such as cancerous cell) surface, one or more microRNA target sequences with the one or more copies being inserted in one or more HSV gene (preferably HSV replicates required one or more HSV genes in normal (that is, non-cancerous) cell) seat.Invention further provides stock solution and the pharmaceutical composition of the oHSV comprising innovation, and use the method that the oHSV of described innovation kills tumor cell.
